Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches. Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants. Sharing of one class I II will be considered eligible for participation in the study. Peripheral blood and PBMC from the donors will be isolated, washed and irradiated. The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Hadassah Medical Organization
Jerusalem, Israel
Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.
To induce immunity against a putative bcr/abl peptide bound to MHC identical class I, II or preferably both.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.